Atea Pharmaceuticals (AVIR) Gains as COVID Drug Highlighted by NYT

June 17, 2021 11:13 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Atea Pharmaceuticals Inc. (NASDAQ: AVIR) gains intra-day as New York Times discusses 'A pill to treat COVID-19', which highlights the company's AT-527.

From the article:

"One of the drugs the government is considering is AT-527, developed by Atea Pharmaceuticals. The compound has already proven safe and effective as a treatment for hepatitis C, and early studies suggested it might also work against Covid-19. Roche has partnered with Atea to test it in people, and the companies are currently running a late-stage clinical trial."

Shares of AVIR are up 6% intra-day.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk